Renaiss Launches Open Beta: On-chain User Identity Import, New Card Pack Sells Out in 22 Minutes
BlockBeats News, December 19, Renaiss Protocol announced the official launch of Open Beta. The first round simultaneously released the new card pack "Pikasso," with the single-round supply quantity doubled from the previous testing phase to a total of 2,000 cards. The pack was sold out in 22 minutes after launch, continuing the market heat from the internal testing phase.
This Open Beta brings many core updates, including the SBT badge system, used to record user participation and growth status on the platform. The first batch of SBT has been airdropped, and users can view and share their SBT and collectible cards on their profile page. Meanwhile, the invitation code system has been upgraded to a single invitation link referral model. Additionally, the platform will launch a new liquidity event called SuperLiquid, which incentivizes order placement, bidding, and transaction behavior through a multi-dimensional mechanism to enhance market liquidity and depth.
On the same evening, Renaiss founder Winchman participated in a themed AMA with the BNB Chain, discussing the product direction, mechanism design, and future plans and community engagement during the Open Beta phase.
Renaiss stated that Open Beta will serve as a crucial stage for comprehensive product and mechanism expansion, with continuous releases of more features and gameplay updates in the future.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.
The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).
China’s gold imports exceeded 1,000 tons by August, surpassing the total for all of 2025.
Crypto prices
More
